What is the market price of Pitobrutinib/Pitobrutinib after it is launched in China?

Pirtobrutinib is a new generation of highly selective BTK inhibitors and is considered an important breakthrough in the field of hematological tumors. BTK inhibitors first emerged in the treatment of chronic lymphocytic leukemia and mantle cell lymphoma, but traditional drugs often have problems such as drug resistance and adverse reactions. Pitobrutinib has been greatly optimized in its molecular structure design, and is characterized by its ability to effectively inhibit abnormal signaling that persists after BTK mutations. Therefore, it has shown significant application value in some patient groups that are resistant to other BTK inhibitors. The development and clinical use of this drug provides new treatment options for patients with hematological tumors, and also makes labels such as “refractory and relapsed” no longer the only outcomes.

At the application level, pitubrutinib mainly targets chronic lymphocytic leukemia, mantle cell lymphoma and other B-cell malignant tumors. It has been included in the recommendations in overseas guidelines and clinical practice. Its high selectivity and oral dosage form improve patients' medication compliance and have advantages over earlier drugs in terms of tolerability. As more real-world data accumulate, the clinical value of this drug is gradually being confirmed.

Regarding the market price, Pitobrutinib has been introduced by the original manufacturer and approved for marketing in China, but it has not yet been included in the medical insurance catalog. The current specifications on the market are 100 mg, 14 tablets, and 4 tablets, and each box is priced at more than 40,000 yuan. Compared with overseas markets, China's selling prices generally remain at international price levels, but due to the lack of medical insurance coverage, the financial burden on patients is greater. Industry experts predict that as medical insurance negotiations advance and generic drugs are gradually developed, prices are expected to drop in the future, thus benefiting more patients. It can be said that pitubrutinib not only represents the direction of a new type of targeted drug, but also reflects the game between clinical demand and price accessibility of tumor drugs.

Reference materials:https://go.drugbank.com/drugs/DB17472